Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway

被引:15
作者
Zhang, Ji [1 ]
Wang, Xue-jun [1 ]
Wu, Li-jie [1 ,2 ]
Yang, Ling [3 ]
Yang, Yan-ting [3 ]
Zhang, Dan [3 ]
Hong, Jue [3 ]
Li, Xi-ying [1 ]
Dong, Xiao-qing [1 ]
Guo, Xiao-cong [1 ]
Han, Rong [1 ]
Ma, Xiaopeng [1 ,3 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Yueyang Clin Med Sch, Shanghai, Peoples R China
[2] Zhejiang Prov Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Key Lab Acupuncture Moxibust & Immunol, Shanghai Res Inst Acupuncture & Meridian, Shanghai, Peoples R China
来源
PLOS ONE | 2021年 / 16卷 / 05期
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
NF-KAPPA-B; P2X7; RECEPTOR; PANNEXIN-1; CHANNELS; ULCERATIVE-COLITIS; A20; EXPRESSION; MOUSE MODEL; CELLS; ACTIVATION; BLOCKADE;
D O I
10.1371/journal.pone.0252334
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Crohn's disease is a chronic inflammatory bowel disease and the NLRP3 inflammasome plays an important role in Crohn's disease. Previous studies have shown that Herb-partitioned moxibustion treating (at Qihai (CV 6) and Tianshu (ST 25)) prevented the excessive activation of the NLRP3 inflammasome and repaired damaged colonic mucosa in Crohn's disease. However, the mechanism by which Herb-partitioned moxibustion (at CV 6 and ST 25) regulates NLRP3 remains unclear. In this study, we treated Crohn's disease rats with herb-partitioned moxibustion (at CV 6 and ST 25) to investigate the mechanism by which Herb-partitioned moxibustion regulates the colonic NLRP3 inflammasome by observing colon length, the colon macroscopic damage indexes, and the expression of ATP, P2X7R, Pannexin-1, NF-kappa Bp65, NLRP3, ASC, caspase-1, IL-1 beta and IL-18 in the colon in Crohn's disease. Here, this study shows that herb-partitioned moxibustion (at CV 6 and ST 25) can reduce colon macroscopic damage indexes and colon histopathological scores, alleviate colon shortening and block the abnormal activation of the NLRP3 inflammasome by inhibiting the ATP content and the expression of P2X7R, Pannexin-1 and NF-kappa Bp65, thereby reducing the release of the downstream inflammatory cytokine IL-1 beta and ultimately suppressing colonic inflammation in Crohn's disease rats. This study for the first time identifies the mechanism by which herb-partitioned moxibustion (at CV 6 and ST 25) may inhibit the abnormal activation of the NLRP3 inflammasome by inhibiting the P2X7R-Pannexin-1 signaling pathway in Crohn's disease rats.
引用
收藏
页数:21
相关论文
共 65 条
  • [1] The P2X7 receptor: A main player in inflammation
    Adinolfi, Elena
    Giuliani, Anna Lisa
    De Marchi, Elena
    Pegoraro, Anna
    Orioli, Elisa
    Di Virgilio, Francesco
    [J]. BIOCHEMICAL PHARMACOLOGY, 2018, 151 : 234 - 244
  • [2] T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells
    Arbore, Giuseppina
    West, Erin E.
    Spolski, Rosanne
    Robertson, Avril A. B.
    Klos, Andreas
    Rheinheimer, Claudia
    Dutow, Pavel
    Woodruff, Trent M.
    Yu, Zu Xi
    O'Neill, Luke A.
    Coll, Rebecca C.
    Sher, Alan
    Leonard, Warren J.
    Koehl, Jorg
    Monk, Pete
    Cooper, Matthew A.
    Arno, Matthew
    Afzali, Behdad
    Lachmann, Helen J.
    Cope, Andrew P.
    Mayer-Barber, Katrin D.
    Kemper, Claudia
    [J]. SCIENCE, 2016, 352 (6292)
  • [3] Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile
    Argollo, Marjorie
    Kotze, Paulo Gustavo
    Lamonaca, Laura
    Gilardi, Daniela
    Furfaro, Federica
    Yamamoto, Takayuki
    Danese, Silvio
    [J]. CURRENT DRUG TARGETS, 2019, 20 (13) : 1327 - 1338
  • [4] The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
    Bartlett, Rachael
    Stokes, Leanne
    Sluyter, Ronald
    [J]. PHARMACOLOGICAL REVIEWS, 2014, 66 (03) : 638 - 675
  • [5] Crohn's disease
    Baumgart, Daniel C.
    Sandborn, William J.
    [J]. LANCET, 2012, 380 (9853) : 1590 - 1605
  • [6] Management of Active Crohn Disease
    Cheifetz, Adam S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (20): : 2150 - 2158
  • [7] Systematic review with meta-analysis: Safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas
    Ciccocioppo, Rachele
    Klersy, Catherine
    Leffler, Daniel A.
    Rogers, Raquel
    Bennett, Dimitri
    Corazza, Gino Roberto
    [J]. JGH OPEN, 2019, 3 (03): : 249 - 260
  • [8] Optimizing Immunomodulators and Anti-TNF Agents in the Therapy of Crohn Disease
    Dassopoulos, Themistocles
    Sninsky, Charles A.
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2012, 41 (02) : 393 - +
  • [9] The P2X7 Receptor in Infection and Inflammation
    Di Virgilio, Francesco
    Dal Ben, Diego
    Sarti, Alba Clara
    Giuliani, Anna Lisa
    Falzoni, Simonetta
    [J]. IMMUNITY, 2017, 47 (01) : 15 - 31
  • [10] Blockade of Pannexin-1 Channels and Purinergic P2X7 Receptors Shows Protective Effects Against Cytokines-Induced Colitis of Human Colonic Mucosa
    Diezmos, Erica F.
    Markus, Irit
    Perera, D. S.
    Gan, Steven
    Zhang, Li
    Sandow, Shaun L.
    Bertrand, Paul P.
    Liu, Lu
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9